

Genetic Signatures Announces Strategic Partnership with Tecan and Repado to Deliver Enhanced, Scalable, Fully Automated Infectious Disease Testing Solutions

Genetic Signatures [ASX:GSS] (“GSS” or “the Company”), a global molecular diagnostics company is pleased to announce a strategic partnership with **Tecan**, a world-renowned provider of laboratory automation solutions, and **Repado**, a leading developer of compliant IVD software platforms.

HIGHLIGHTS

- The partnership between Tecan, Repado and Genetic Signatures has been established to deliver an enhanced automated solution to market; *and*
- The first phase of the project has commenced with both partners

A fully integrated, sample-to-answer ecosystem

The partnership enables the development of a **scalable suite of fully automated diagnostic platforms** designed for syndromic testing laboratories. These systems will seamlessly integrate:

- **Tecan’s scalable liquid handling platforms** for a sample-to-result solution
- **Repado’s modular, configurable software** built specifically for **IVD regulatory standards** (IVDR, FDA), data integrity, and user workflow
- **Genetic Signatures’ infectious disease assay portfolio**, initially including Respiratory, Gastrointestinal, and Sexually Transmitted Infection panels

“This partnership accelerates our mission to simplify and scale syndromic molecular diagnostics globally,” said Allison Rossiter, CEO of Genetic Signatures. “By aligning with trusted partners like Tecan and Repado, we can offer our customers complete solutions — from sample to result — with built-in compliance, quality, and performance.”

Platform enabling efficiency, compliance and scalability

The new platform will deliver:

- **Automation of complex molecular workflows**, reducing hands-on time and operator error
- **Regulatory-ready design** aligned with IVDR, FDA, and ISO 13485 standards
- **Flexible deployment** across central labs, hospital networks, and global distribution partners

"At Tecan, we are committed to empowering our IVD partners with innovative automation solutions that drive efficiency, accuracy, and scalability," said Madhu Vasudevamurthy, SVP IVD & Life Sciences Partnering at Tecan. "Our partnership with Genetic Signatures brings together complementary expertise to deliver a truly integrated, sample-to-answer platform. By combining our proven automation technology with advanced molecular diagnostics, we are supporting Genetic Signatures in enabling laboratories worldwide to meet the growing demands of infectious disease testing."

"We are excited to be part of this strategic partnership that brings together Genetic Signatures' pioneering chemistry, Tecan's state-of-the-art automation, and Repado's purpose-built compliant software," said Kostas Delakouridis, CEO of Repado.

"With scalability and regulatory alignment at its core, Repado's software platform supports laboratories in meeting evolving requirements under demanding frameworks (IVDR/FDA). This collaboration combines three essential pillars: cutting-edge chemistry, precision automation, and robust software, delivering streamlined operations and faster, more reliable diagnostics."

Market impact from the testing solution

The first concept systems are currently in development with early access planned for select global reference labs and clinical partners.

This collaboration represents a significant leap forward for Genetic Signatures in offering consolidated infectious disease testing. The solution will enable laboratory efficiencies, complete automation and regulatory compliance.

Genetic Signatures has also initiated a comprehensive development program to support the expansion of its **3base®** technology syndromic infectious disease menu, which will be launched alongside the new integrated hardware and software solution.

– END –

Announcement authorised by Genetic Signatures' Board of Directors

For further information, see our website (www.geneticsignatures.com) or contact us:

Allison Rossiter

Chief Executive Officer

allison.rossiter@geneticsignatures.com

T: +61 (0)2 9870 7580

Karl Pechmann

Chief Financial Officer

karl.pechmann@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base®**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures' proprietary MDx **3base®** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.